Company / Financials
IGC Pharma, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.3M
FY2025 · +39.5% YoY
Net Income
-$7.1M
FY2025 · +38.1% YoY
Profit Margin
-560.4%
FY2025 · net income / revenue
ROE
-112.5%
FY2025 · return on equity
Total Assets
$8.7M
FY2025
Total Debt
$134.0K
0.02x debt/equity
Equity
$6.3M
FY2025
ROA
-81.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.3M+39.5% YoYNet Income HistoryProfit after all expenses and taxes-$7.1M+38.1% YoYGross Profit HistoryRevenue minus cost of goods sold$619.0K+40.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$652.0K+39.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$7.4M+35.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$4.4M-48.4% YoYR&D Expense HistoryResearch and development spending$3.7M+5.6% YoYInterest Expense HistoryCost of borrowing and debt obligations$5.0K0.0% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.22